Wealthfront Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealthfront Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.7M	Sell	41,608 -4,787	-10%	-$2.12M	0.04%	153
2026 Q1	$20.7M	Buy	46,395 +3,226	+7%	+$1.5M	0.05%	138
2025 Q4	$19.6M	Buy	43,169 +5,796	+16%	+$2.5M	0.04%	135
2025 Q3	$14.6M	Sell	37,373 -6,545	-15%	-$2.74M	0.03%	166
2025 Q2	$19.6M	Sell	43,918 -3,014	-6%	-$1.39M	0.05%	119
2025 Q1	$22.8M	Buy	46,932 +5,913	+14%	+$2.76M	0.06%	97
2024 Q4	$16.5M	Buy	41,019 +1,819	+5%	+$843K	0.05%	118
2024 Q3	$18.2M	Sell	39,200 -490	-1%	-$235K	0.06%	97
2024 Q2	$18.6M	Sell	39,690 -707	-2%	-$307K	0.06%	87
2024 Q1	$16.9M	Sell	40,397 -263	-0.6%	-$111K	0.06%	94
2023 Q4	$16.5M	Sell	40,660 -605	-1%	-$223K	0.06%	84
2023 Q3	$14.3M	Sell	41,265 -356	-0.9%	-$125K	0.06%	89
2023 Q2	$14.6M	Buy	41,621 +1,742	+4%	+$587K	0.06%	84
2023 Q1	$12.6M	Buy	39,879 +4,883	+14%	+$1.46M	0.06%	99
2022 Q4	$10.1M	Sell	34,996 -3,525	-9%	-$1.07M	0.05%	114
2022 Q3	$11.2M	Buy	38,521 +4,596	+14%	+$1.32M	0.06%	82
2022 Q2	$9.56M	Buy	33,925 +18,566	+121%	+$4.97M	0.05%	97
2022 Q1	$4.01M	Buy	15,359 +8,236	+116%	+$1.95M	0.02%	247
2021 Q4	$1.56M	Buy	7,123 +1,425	+25%	+$277K	0.01%	431
2021 Q3	$1.03M	Buy	5,698 +26	+0.5%	+$5.08K	﹤0.01%	465
2021 Q2	$1.14M	Sell	5,672 -3,869	-41%	-$809K	0.01%	414
2021 Q1	$2.05M	Buy	9,541 +1,260	+15%	+$277K	0.01%	260
2020 Q4	$1.96M	Sell	8,281 -930	-10%	-$213K	0.01%	234
2020 Q3	$2.51M	Sell	9,211 -5	-0.1%	-$1.38K	0.02%	144
2020 Q2	$2.67M	Buy	9,216 +930	+11%	+$252K	0.02%	123
2020 Q1	$1.97M	Buy	8,286 +1,133	+16%	+$260K	0.02%	146
2019 Q4	$1.57M	Buy	7,153 +597	+9%	+$121K	0.01%	232
2019 Q3	$1.11M	Sell	6,556 -632	-9%	-$112K	0.01%	270
2019 Q2	$1.32M	Buy	7,188 +213	+3%	+$37.2K	0.01%	222
2019 Q1	$1.28M	Buy	6,975 +135	+2%	+$24.9K	0.01%	214
2018 Q4	$1.13M	Buy	+6,840	New	+$1.19M	0.01%	215

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wealthfront Advisers's VRTX Position: Q2 2026 in Review

Wealthfront Advisers reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, selling an estimated $2.12M and leaving 41,608 shares worth $20.7M. The position accounts for 0.04% of the portfolio, ranked #153.

Wealthfront Advisers first reported a position in VRTX in Q4 2018 and has held it in 31 quarters since. The position peaked at $22.8M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Wealthfront Advisers held 41,608 shares of Vertex Pharmaceuticals worth $20.7M as of Q2 2026.
Wealthfront Advisers sold 4,787 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.12M.
Vertex Pharmaceuticals made up 0.04% of Wealthfront Advisers's portfolio in Q2 2026, its #153 holding.
Wealthfront Advisers first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
Wealthfront Advisers's Vertex Pharmaceuticals position peaked at $22.8M in Q1 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.